

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Glicklich Alan</u>  (Last) (First) (Middle) <u>C/O CHINOOK THERAPEUTICS, INC.</u> <u>1600 FAIRVIEW AVE. E.</u>  (Street) <u>SEATTLE</u> <u>WA</u> <u>98102</u>  (City) (State) (Zip)	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>ADURO BIOTECH, INC.</u> [ <u>KDNY</u> ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  <input checked="" type="checkbox"/> Director 10% Owner <input type="checkbox"/> Officer (give title below) Other (specify below)  <u>Chief Medical Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/05/2020</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
<u>Stock Option (right to buy)</u>	<u>\$0.42</u>	<u>10/05/2020</u>		<u>A</u>		<u>242,662</u>		<u>(1)</u>	<u>04/21/2030</u>	<u>Common Stock</u>	<u>242,662</u>	<u>(2)</u>	<u>242,662</u>	<u>D</u>	
<u>Stock Option (right to buy)</u>	<u>\$14.77</u>	<u>10/06/2020</u>		<u>A</u>		<u>62,660</u>		<u>(3)</u>	<u>10/05/2030</u>	<u>Common Stock</u>	<u>62,660</u>	<u>\$0.00</u>	<u>62,660</u>	<u>D</u>	
<u>Restricted Stock Units (RSU) (Common Stock)</u>	<u>(4)</u>	<u>10/06/2020</u>		<u>A</u>		<u>21,311</u>		<u>(5)</u>	<u>10/05/2030</u>	<u>Common Stock</u>	<u>21,311</u>	<u>\$0.00</u>	<u>21,311</u>	<u>D</u>	

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on April 20, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
2. Received in connection with the merger of Private Chinook into the Issuer in exchange for a stock option to acquire 830,500 shares of Private Chinook common stock for \$0.12 per share.
3. The stock option vests as to 25% of the total shares on October 6, 2021, and thereafter vests as to 1/36 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
5. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on October 6, 2021, until fully vested subject to the reporting person's provision of service to the Issuer on each vesting date.

Remarks:

/s/ Kirk Schumacher, Attorney-in-Fact 10/07/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.